

TABLE I DOSING ERRORS BY INSTRUMENT

Parameter		Dosing cup	Syringe	Dropper
Mean dose, mL (SD)		4.9 (1.0)	4.3 (1.0)	0.56 (0.37)
No error†‡	Higher dose <i>n</i> (%)	150 (47.1)	75 (23.6)	44 (13.8)
	Lower dose <i>n</i> (%)	92 (28.9)	166 (52.2)	143 (44.9)
Small dosing error†‡	Overdose <i>n</i> (%)	23 (7.2)	0	3 (0.9)
	Under-dose <i>n</i> (%)	26 (8.1)	41 (12.9)	21 (6.6)
Large dosing error†‡	Overdose <i>n</i> (%)	4 (1.3)	0	1 (0.3)
	Under-dose <i>n</i> (%)	23 (7.2)	36 (11.3)	106 (33.3)

The parent was asked to measure 5mL with dosing cup and syringe; 1mL with the dropper; † No error: up to 20% deviation from recommended dose; small error: 20-40% deviation; large error: more than 40% deviation from recommended dose; ‡ $P < 0.001$ for comparison of dosing error categories between device types.

S R Ravikiran and Y M Shivarajashankara*
*Departments of Pediatrics and *Biochemistry,
 KVG Medical College and Hospital,
 Sullia, Dakshina Kannada,
 Karnataka, India.*

REFERENCES

1. Yin HS, Mendelsohn AL, Wolf MS, Parker RM, Fierman A, van Schaick L, *et al.* Parents' medication administration errors: role of dosing instruments and health literacy. *Arch Pediatr Adolesc Med.* 2010;164:181-6.
2. Madlon-Kay DJ, Mosch FS. Liquid medication dosing errors. *J Fam Pract.* 2000;49:741-4.
3. Sobhani P, Christopherson J, Ambrose PJ, Corelli RL. Accuracy of oral liquid measuring devices: comparison of dosing cup and oral dosing syringe. *Ann Pharmacother.* 2008;42:46-52.
4. Yin HS, Dreyer BP, van Schaick L, Foltin GL, Dinglas C, Mendelsohn AL. Randomized controlled trial of a pictogram-based intervention to reduce liquid medication dosing errors and improve adherence among caregivers of young children. *Arch Pediatr Adolesc Med.* 2008;162:814-22.

Neonatal Screening for Hemoglobinopathies

A pilot study was undertaken to develop a feasible neonatal screening strategy for hemoglobinopathies. Isoelectric focusing using dried blood spots samples as a primary screening technique was standardized for the first time in India. The screened positives were confirmed by high performance liquid chromatography followed by parental screening, confirmation, and education.

Key words: Hemoglobinopathy, India, Isoelectric focusing, Neonatal screening, Prevention.

Hemoglobinopathies cause high degree of morbidity and mortality in India [1], there is an urgent need to detect the disorders as soon as possible after birth. We conducted a pilot study aiming to develop a feasible neonatal screening strategy. Following informed consent from parents, dried blood spot (DBS) samples were collected from 207 inborn babies within day 3-7 of life, over a period of two months. Primary screening by isoelectric focusing (IEF) (Perkin Elmer, Finland) [2] was done within 7 days of sample collection. Results were interpreted using ISOSCAN software (Perkin Elmer, Finland). The screened positive babies were recalled for confirmation by high-performance liquid chromatography (HPLC) (Biorad Laboratories)

using anticoagulated blood at a reference laboratory. Parents of the positive babies were also screened and confirmed. Complete hemogram of the recalled babies and parents was performed. Repeat screening by IEF as well as HPLC of 20 screen negative babies were performed to check whether the technique of IEF gives false negatives or not.

Among four babies positive for hemoglobinopathies, three had Hb E trait and one had HbE disease. All were term babies and clinically asymptomatic, with average hemoglobin concentration 9.6 g/dL. All the mothers of Hb E trait babies were carriers of Hb E. The father of the baby with Hb E disease was a carrier while the mother was affected with Hb E disease. After counselling the parents, the babies were referred to our outpatient department for further management and follow up.

We tried to develop a feasible screening program in our institute, which could subsequently be adapted in all parts of the country. The use of DBS samples ensures that samples might be easily transported without any special facilities with low probability of transmitting blood borne pathogens [4,5]. The results of repeat IEF and HPLC using anticoagulated blood matched with that of IEF results performed by DBS samples, thereby proving the stability of hemoglobin in DBS. Moreover, the results of the repeat testing of the screen negative babies matched with the first screening result of IEF and that of HPLC. IEF along with the ISOSCAN software was standardized for the first time in India, since it is a reliable [6] and cost effective screening tool. In the study, IEF results matched with the HPLC results, the gold standard method widely used in India for detecting hemoglobinopathies. IEF was able to differentiate between the heterozygote and homozygote cases. One limitation of the technique in common with HPLC is the inability to identify beta thalassemia traits in neonates. For this, babies need

to be screened at the age of six months or more when the switching of Hb F to Hb A is usually complete.

We conclude that implementation of a neonatal screening program for hemoglobinopathies is feasible in India.

Acknowledgments: NRS Medical College & Hospital, Kolkata for providing HPLC free of cost and Mr Fred Meindl (Perkin Elmer Health Sciences, Mexico) for training and interpretations of IEF results in neonates.

Contributors: MB and RV conducted the experiments and prepared the initial draft of the paper. SD and AKS helped with the patient information and approved the final draft of the paper.

Funding: None.

Competing interests: None stated.

**Madhura Bose, Rajlakshmi Viswanathan,
Sudipta Dasgupta and Arun K Singh**
*Department of Neonatology, IPGME&R-SSKM
Hospital, Kolkata 700 020, India.
drarunsingh61@gmail.com.*

REFERENCES

1. Kapoor S, Kabra M. Newborn screening in India: Current perspectives. *Indian Pediatr.* 2010;47:219-24.
2. Galacteros F, Kleman K, Caburi-Martin J, Beuzard Y, Rosa J, Lubin B. Cord blood screening for hemoglobin abnormalities by thin layer isoelectric focusing. *Blood.* 1980;56:1068-71.
3. Gulbis B, Cotton F, Ferster A, Ketelslegers O, Dresse MF, Ronge-Collard E, *et al.* Neonatal hemoglobinopathy screening in Belgium. *J Clin Pathol.* 2008;62:49-52.
4. Ad Hoc Newborn Screening Committee, National Sickle Cell Disease Advisory Committee. *Newborn Screening for Hemoglobinopathies: Program Development Laboratory Methods.* Bethesda, MD: Sickle Cell Disease Branch, National Institutes of Health; 1990.
5. Fairbanks VP, Klee GG. Biochemical aspects of hematology. *In:* Tietz NW, editor. *Textbook of Clinical Chemistry.* Philadelphia: WB Saunders. 1986. p. 1542-8.
6. Paixao MC, Ferraz MHC, Januario JN, Viana MB, Viana MB, Lima JM. Reliability of Isoelectric focusing for the detection of Hb S, Hb C, and Hb D in a pioneering population-based program of newborn screening in Brazil. *Hemoglobin.* 2001;25:297-303.